Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 5/20 | 0.75 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.48 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11833855 | 0.88 | PTGS1 (0.80) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| Fenoprofen SCHEMBL3797 | 0.86 | PTGS1 (1.00) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| (S)-Fenoprofen SCHEMBL4492279 | 0.86 | PTGS1 (1.00) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| R-Fenoprofen SCHEMBL4082 | 0.86 | PTGS1 (1.00) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| R-Fenoprofen SCHEMBL30910976 | 0.86 | PTGS1 (1.00) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| Fenoprofen SCHEMBL11336376 | 0.86 | PTGS1 (1.00) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| Fenoprofen SCHEMBL8754928 | 0.86 | PTGS1 (1.00) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| Fenoprofen SCHEMBL29481372 | 0.86 | PTGS1 (1.00) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| Fenoprofen SCHEMBL11125651 | 0.84 | PTGS1 (0.97) | PTGS1MEN1CYP2D6KMT2APTGS2 | |
| Fenoprofen SCHEMBL4081 | 0.84 | PTGS1 (0.97) | PTGS1MEN1CYP2D6KMT2APTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-01-27 | — | — | US | disclosed |
| WO-2009059239-A2 | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | APP, BACE1, GAP43 | PTGS1 2370/4885MEN1 2435/4885CYP2D6 4839/4885 |
| US-20080021085-A1 | METHOD OF REDUCING ABETA42 AND TREATING DISEASES | BACE1, BACE2, APP | PTGS1 1377/4885MEN1 1816/4885CYP2D6 2583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.